Literature DB >> 8977595

Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction.

P Zanen1, L T Go, J W Lammers.   

Abstract

BACKGROUND: The optimal particle size of a beta 2 agonist or anticholinergic aerosol in patients with severe airflow obstruction is unknown.
METHODS: Seven stable patients with a mean forced expiratory volume in one second (FEV1) of 37.9% of the predicted value inhaled three types of monodisperse salbutamol and ipratropium bromide aerosols with particle sizes of 1.5 microns, 2.8 microns, and 5 microns, respectively, and a placebo aerosol. The volunteers inhaled 20 micrograms salbutamol and 8 micrograms ipratropium bromide, after which lung function changes were determined and analysed with repeated measurements analysis of variance (ANOVA).
RESULTS: Greater improvements in FEV1, specific airway conductance (sGaw) and maximum expiratory flow at 75%/50% of the forced vital capacity (MEF75/50) were induced by the 2.8 microns aerosol than by the other particle sizes.
CONCLUSIONS: In patients with severe airflow obstruction the particle size of choice for a beta 2 agonist or anticholinergic aerosol should be approximately 3 microns.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8977595      PMCID: PMC472643          DOI: 10.1136/thx.51.10.977

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  3 in total

1.  Respiratory tract deposition of ultrafine particles in subjects with obstructive or restrictive lung disease.

Authors:  P J Anderson; J D Wilson; F C Hiller
Journal:  Chest       Date:  1990-05       Impact factor: 9.410

2.  Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurised metered dose inhaler, as a dry powder, and as a nebulised solution.

Authors:  B M Zainudin; M Biddiscombe; S E Tolfree; M Short; S G Spiro
Journal:  Thorax       Date:  1990-06       Impact factor: 9.139

Review 3.  Deposition, retention, and clearance of inhaled particles.

Authors:  M Lippmann; D B Yeates; R E Albert
Journal:  Br J Ind Med       Date:  1980-11
  3 in total
  19 in total

Review 1.  Methods to identify drug deposition in the lungs following inhalation.

Authors:  H Chrystyn
Journal:  Br J Clin Pharmacol       Date:  2001-04       Impact factor: 4.335

Review 2.  Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications.

Authors:  N R Labiris; M B Dolovich
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

Review 3.  Aerosol deposition in health and disease.

Authors:  Chantal Darquenne
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2012-06       Impact factor: 2.849

4.  Inhalation devices.

Authors: 
Journal:  CMAJ       Date:  2005-09-13       Impact factor: 8.262

5.  Product Quality Research Institute evaluation of cascade impactor profiles of pharmaceutical aerosols. Part 3. Final report on a statistical procedure for determining equivalence.

Authors:  David Christopher; Wallace Adams; Anthony Amann; Craig Bertha; Peter R Byron; William Doub; Craig Dunbar; Walter Hauck; Svetlana Lyapustina; Jolyon Mitchell; Beth Morgan; Steve Nichols; Ziqing Pan; Gur Jai Pal Singh; Terrence Tougas; Yi Tsong; Ron Wolff; Bruce Wyka
Journal:  AAPS PharmSciTech       Date:  2007-11-02       Impact factor: 3.246

Review 6.  In vitro and in vivo aspects of cascade impactor tests and inhaler performance: a review.

Authors:  Jolyon Mitchell; Steve Newman; Hak-Kim Chan
Journal:  AAPS PharmSciTech       Date:  2007-12-21       Impact factor: 3.246

Review 7.  The Impact of Inspiratory Flow Rate on Drug Delivery to the Lungs with Dry Powder Inhalers.

Authors:  Jeffry Weers; Andy Clark
Journal:  Pharm Res       Date:  2016-10-13       Impact factor: 4.200

8.  Characterisation and deposition studies of recrystallised lactose from binary mixtures of ethanol/butanol for improved drug delivery from dry powder inhalers.

Authors:  Waseem Kaialy; Gary P Martin; Martyn D Ticehurst; Paul Royall; Mohammad A Mohammad; John Murphy; Ali Nokhodchi
Journal:  AAPS J       Date:  2010-11-06       Impact factor: 4.009

9.  Assessment and Validation of a Hygroscopic Growth Model with Different Water Activity Estimation Methods.

Authors:  Patrick T O'Shaughnessy; Lawrence LeBlanc; Alessandra Pratt; Ralph Altmaier; Prathish K Rajaraman; Ross Walenga; Ching-Long Lin
Journal:  Aerosol Sci Technol       Date:  2020-05-19       Impact factor: 2.908

Review 10.  In vitro considerations to support bioequivalence of locally acting drugs in dry powder inhalers for lung diseases.

Authors:  Sau Lawrence Lee; Wallace P Adams; Bing V Li; Dale P Conner; Badrul A Chowdhury; Lawrence X Yu
Journal:  AAPS J       Date:  2009-06-03       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.